Table 1.
Characteristics of ALL patients included in ABL fusion marker study.
| ID | ALL type | ABL Fusion | Recurrent IKZF1del | Sex | Age (years) | Front-line therapy | End of Induction MRD (d28-35) | Relapse/SMN (mo) | Later therapy | HSCT (stage) | Death (mo) | Current Status | Discordant MRD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | B | EBF1-PDGFRB | IKZF1 4-7 | M | 5 | BFM, no TKI | 6 × 10–2 | 23 | ALLR3, no TKI | CR1 + CR2 | CR2 | No | |
| 2 | B | EBF1-PDGFRB | neg | F | 11 | BFM, no TKI | 1 × 10–0 rel | 37 | ALLR3, no TKI | CR2 | 45 | deceased | No |
| 3 | B | EBF1-PDGFRB | IKZF1 4-7 | M | 14 | BFM, no TKI | 1 × 10–0 | – | CR1 | CR1 | No | ||
| 4 | B | EBF1-PDGFRB | neg | M | 3 | BFM, no TKI | 1 × 10–2 | 30 | ALLR3, imatinib | CR3 | CR3 | No | |
| 5 | B | EBF1-PDGFRB | IKZF1 4-8 | M | 6 | COG, imatinib | 5 × 10–2 | 40 | ALLR3, dasatinib | CR1 + CR2 | CR2 | No | |
| 6 | B | EBF1-PDGFRB | neg | M | 5 | COG, imatinib | 3 × 10–3 | – | – | no | CR1 | No | |
| 7 | B | EBF1-PDGFRB | IKZF1 4-7 | M | 14 | COG, imatinib, dasatinib | 1 × 10–1 | – | – | CR1 | CR1 | No | |
| 8 | B | EBF1-PDGFRB | neg | M | 7 | BFM, imatinib | 3 × 10–1 | – | CR1 | CR1 | No | ||
| 9 | B | EBF1-PDGFRB | scIKZF1 4-7 | F | 15 | COG, dasatinib | 8 × 10–2 | – | no | CR1 | No | ||
| 10 | B | CD74-PDGFRB | IKZF1 4-7 | F | 2 | COG, dasatinib | N/A | – | CAR-T, HSCT | CR1 | CR1 | No | |
| 11 | B | AT7IP-PDGFRB | neg | M | 9 | BFM, dasatinib | 7 × 10–2 | 11 | blinatumomab, CAR-T | CR1 + CR2 | CR3 | No | |
| 12 | B | ETV6-ABL1 | neg | F | 1 | BFM, no TKI | neg | 55 | ALLR3, no TKI | CR1 | CR2 | No | |
| 13 | B | ETV6-ABL1 | scIKZF1 4-7 | F | 1 | COG, no TKI | neg | – | – | no | CR1 | No | |
| 14 | B | IGSF11-ABL1 | IKZF1 4-7 | M | 14 | COG, dasatinib | 1 × 10–0 | – | vinc/steroid; HSCT | CR1 | CR1 | No | |
| 15 | B | SNX2-ABL1 | IKZF1 2-7 | M | 12 | COG, dasatinib | 3 × 10–2 | – | blinatumomab, HSCT | CR1 | CR1 | No | |
| 16 | B | NUP214-ABL1 | IKZF1 4-7 | M | 16 | BFM, dasatinib | 9 × 10–2 | – | – | CR1 | CR1 | No | |
| 17 | B | NUP214-ABL1 | IKZF1 4-7 | M | 12 | COG, imatinib | 4 × 10–1 | – | blinatumomab | CR1 | CR1 | No | |
| 18 | ETP | NUP214-ABL1 | neg | M | 10 | COG, dasatinib | 2 × 10–2 | 29 (SMN) | AML therapy | CR1 + CR2 | 41 | deceased | No |
| 19 | T | NUP214-ABL1 | neg | M | 14 | COG, dasatinib | 7 × 10–1rel | 15 | IntReALL | CR2 | 21 | deceased | No |
| 20 | B | SSBP2-CSF1R | neg | M | <1 | BFM, no TKI | neg | 34 | ALLR3, no TKI | intent | 79 | deceased | No |
| 21 | B | SSBP2-CSF1R | neg | F | 15 | BFM, dasatinib | 2 × 10–2 | – | – | CR1 | 9 | deceased | No |
| Total | B-ALL | IKZF1del | Male | Age (median, range) | Front-line TKI use % | High EOI MRD > 1 × 10–3 (%) | Relapse or SMN | HSCT % | Death | Current CR1 n, % | Discordant MRD | ||
| n = 21 | 90% | ABL-class fusions | 43% | 71% | 10 (0-16) | 67% | 85% | 43% | 81% | 24% | 52% | 0% | |
| n = 44 | 96% | BCR-ABL1 | 59% | 59% | 8 (0-17) | 98% | 66% | 32% | 68% | 16% | 61% | 33% | |
Each of the 21 ABL-class patients are shown in the top section and then summarised for comparison with the BCR-ABL1 patients in the bottom section. Patient 5 was included in Roberts et al. [3].